Everything below concerns systematic review. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-12-15. Numbers and descriptions here follow the published literature rather than marketing material.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | 28 residues; not a small-molecule compound |
| Molecular mass | About 3,106 Da | Monoisotopic mass of the unmodified chain |
| N-terminal group | Acetylated serine | Present in both native and synthetic forms |
| Secondary structure | Disulfide-constrained loop | One bridge between two cysteine residues |
| Typical source | Solid-phase synthesis | Early isolates came from bovine thymus extracts |
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
In the late 1960s and 1979 the Order's membership was reported as 10,000, though the number of lodges fell from 46 to 42 during the same period. The Free Sons had 8,000 members in 1994. In 1923 its headquarters were at 21 W. 124th Street, New York City. The Grand Lodge's current home is 37th Street near 6th Avenue, sharing office space with the Workmens Circle. National convention meets triennially. The Order is led by a "Grand Master", and the other "grand lodge" officers have a "grand" prefix. Has secret rituals, initiation ceremonies, and passwords. Motto "Friendship, Love Truth". Offers members "usual life insurance" benefits; also a Free Sons credit union which gives members low-interest loans. The Order sponsors a scholarship program for Jewish students who show high proficiency in Hebrew, sponsors blood banks, bond drives for United Jewish Appeal, distributes toys for handicapped kids, homes for seniors, convalescent homes and "summer camps for elderly citizens and needy children". There is also a Free Sons Athletic Association which sponsors youth baseball, softball, basketball, bowling, ping pong, golf, and track and field. Improved Order of B'nai B'rith - Founded in 1887 in Baltimore by two lodges of the Independent Order of B'nai B'rith who were dissatisfied with the leadership. Originally had 230 members. By 1899 it had spread to some of the larger cities in the United States east of the Mississippi and had approximately 3,000 members. Membership is open to Hebrew men only.
==== Cause ==== Cause, the open and closed approaches to rhinoplastic correction resolve: (i) nasal pathologies (diseases intrinsic and diseases extrinsic to the nose); (ii) an unsatisfactory aesthetic appearance (disproportion); (iii) a failed primary rhinoplasty; (iv) an obstructed airway; and (v) congenital nose defects and deformities.
The two substrates of this enzyme are propylene glycol and oxidised nicotinamide adenine dinucleotide phosphate (NADP+). Its products are L-lactaldehyde, reduced NADPH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is propane-1,2-diol:NADP+ oxidoreductase. Other names in common use include lactaldehyde (reduced nicotinamide adenine dinucleotide phosphate), reductase, NADP+-1,2-propanediol dehydrogenase, propanediol dehydrogenase, 1,2-propanediol:NADP+ oxidoreductase, and lactaldehyde reductase (NADPH).
=== Post-translational conjugation === This technique fuses protein domains following ribosomal translation of the proteins of interest, in contrast to genetic fusion prior to translation used in other recombinant technologies.
Electron ionization was first described in 1918 by Canadian-American Physicist Arthur J. Dempster in the article of "A new method of positive ray analysis." It was the first modern mass spectrometer and used positive rays to determine the ratio of the mass to charge of various constituents. In this method, the ion source used an electron beam directed at a solid surface. The anode was made cylindrical in shape using the metal which was to be studied. Subsequently, it was heated by a concentric coil and then was bombarded with electrons. Using this method, the two isotopes of lithium and three isotopes of magnesium, with their atomic weights and relative proportions, were able to be determined. Since then this technique has been used with further modifications and developments. The use of a focused monoenergetic beam of electrons for ionization of gas phase atoms and molecules was developed by Bleakney in 1929.
Sources: en.wikipedia.org
According to US Joint Chiefs of Staff Chairman Gen Dan Caine, Trump gave the order to proceed at 23:46 VET (22:46 EST) on 2 January. The administration did not notify the United States Congress in advance of the strikes, saying they had concerns that this could endanger the mission. According to Semafor, The New York Times and The Washington Post knew about the strikes before they were carried out. At least seven explosions were reported at around 02:00 VET (01:00 EST) on 3 January, and low-flying aircraft were seen, predominantly in La Guaira, Higuerote, Meseta de Mamo, Baruta, El Hatillo, Charallave, and Carmen de Uria, most of which are in or near the capital city Caracas.
Creation-science means origin through abrupt appearance in complex form, and includes biological creation, biochemical creation (or chemical creation), and cosmic creation. (...) Creation-science does not include as essential parts the concepts of catastrophism, a world-wide flood, a recent inception of the earth or life, from nothingness (ex nihilo), the concept of kinds, or any concepts from Genesis or other religious texts.
Ackermann, Mackay, and Arnold confirm, "Recent genomic research has shown that hybridization between substantially diverged lineages is the rule, not the exception, in human evolution." Acknowledging that there is still debate over how hybridization shaped human genotypes and phenotypes, the evolutionary biologists assert that hybridization was an essential creative force in the emergence of modern humans. In January 2019, scientists published a chronology for the Pleistocene deposits in the Denisova Cave concluding that at least two groups of humans, including Denisovans, Neanderthals, and related hybrids, occupied the Siberian site from around 300,000 to 20,000 years ago, but more material evidence is needed to prove whether they ever coexisted there. Material data collected at the site, including stone tools, bracelets, and other ornaments suggest that Denisovans may have been capable of higher order thought akin to modern humans. In February 2019, scientists discovered evidence, based on genetics studies using artificial intelligence (AI), that suggest the existence of an unknown human ancestor species, not Neanderthal, Denisovan or human hybrid (like Denny), in the genome of modern humans.
== Risk factors == Glaucoma can affect anyone. Some people have a higher risk or susceptibility to develop glaucoma due to certain risk factors, including increasing age, high intraocular pressure, a family history of glaucoma, and use of steroid medications.
Sources: en.wikipedia.org
== Development == The game was originally created and released by Daniel Fearon. At the time, Fearon was one of the maintainers of the Half-Life fan website Atomic Half-Life, created in anticipation of the game's release. Fearon was sent a copy of Half-Life by Valve prior to its official release, and while playing it, he toyed with the game's code, figuring out how to spawn enemy creatures in multiplayer maps. Fearon's work had initially been done before Valve released the software development kit for Half-Life, requiring him to craft the modification atop the existing Half-Life distribution and to work with multiplayer over slower internet connections, such as phone-line modems. Fearon initially developed a single map that could be played cooperatively, and later a second version with two maps. The first public version of Sven Co-op was released on January 19, 1999, about 3 months after the release of Half-Life. He used the name Sven Co-op to reflect his online handle, "Sven Viking". Contrary to the common belief that Sven Co-op was developed to play through Half-Life cooperatively, Fearon had wanted to create a means for players to engage in cooperative experiences together, often just spawning in large number of enemies for them to dispatch together on a single map. This drew a number of amateur level developers to craft mission-based maps for the mod, where players would be required to go to different areas on the map based on success or failure of a given objective.
=== Natural language processing === Natural language processing (NLP) allows programs to read, write, and communicate in human languages. Specific problems include speech recognition, speech synthesis, machine translation, information extraction, information retrieval, and question answering. Early work, based on Noam Chomsky's generative grammar and semantic networks, had difficulty with word-sense disambiguation unless restricted to small domains called "micro-worlds" (due to the common sense knowledge problem). British linguist and philosopher Margaret Masterman believed it was meaning and not grammar that was the key to understanding languages, and that dictionaries and especially thesauri should be the basis of computational language structure. Modern deep learning techniques for NLP include word embedding (representing words, typically as vectors encoding their meaning), transformers (a deep learning architecture using an attention mechanism), and others. In 2019, generative pre-trained transformer (or "GPT") language models began to generate coherent text. By 2023, these models were able to get human-level scores on the bar exam, SAT (Scholastic Assessment Test), GRE (Graduate Record Examination), and many other real-world applications.
(2026) study the composition of the Quaternary small mammal assemblage from the Araras Ravine at the Lajedo de Soledade site (Rio Grande do Norte, Brazil), providing evidence of similarities with extant faunas from open environments in the Caatinga and Cerrado. A study on the late Pleistocene/early Holocene fauna from the Pikimachay Cave (Peru) is published by Yataco et al. (2026), who interpret the studied site as likely to be a giant ground sloth burrow that was also used by carnivores and/or humans. Hullot et al. (2026) propose a standardized methodological framework for the study of enamel histology in fossil taxa, and apply it to the study of enamel histology and growth of molars of toxodont notoungulates Pleurostylodon modicus, Eurygenium pacegnum, Adinotherium ovinum and Nesodon imbricatus. Von Koenigswald (2026) reviews the morphological diversity of incisors and canines in extant and fossil mammals. Wilson et al. (2026) compare the wear of bilophodont teeth in xenungulates, pyrotheres, fossil and modern tapirs and in extant marsupials, and interpret their findings as suggestive of browsing feeding behaviors of xenungulates and fossil tapirs, as well as of variable diets of different members of Pyrotheria. Evidence of preservation of amino acids in tooth enamel of fossil proboscideans, equids and rhinocerotids dating back as far as 48 million years is presented by Gatti et al. (2026). Herrando-Pérez et al.
Sources: en.wikipedia.org
Its sequence corresponds to the amino-terminal portion of prothymosin alpha, a larger protein present in many cell types. The isolated 28-residue peptide is a fragment of that protein rather than a separately encoded molecule, and laboratory material is produced by synthesis.
The single bridge between two cysteine residues holds the chain in a folded loop that influences its shape and its behavior in solution. Loss of the bridge through reduction or oxidation shifts chromatographic retention and is tracked during stability work.
It is a defined 28-residue sequence derived from a larger precursor, whereas many other thymic preparations are mixtures of several polypeptides. Its acetylated amino terminus and single disulfide bridge distinguish it chemically from unrelated thymic extracts.
It corresponds to the first 28 amino acids of thymosin beta-4, a larger protein found in many tissues. The fragment is acetylated at its N-terminus and is produced synthetically for research and pharmaceutical use. Synthetic and natural forms share the same sequence.